Xana khensa ya nhlaribya ya vununa yi dlaya ku fikela kwihi?
Khensa ya nhlaribya ya vununa i khensa ya vumbirhi leyi tolovelekeke eka vavanuna emisaveni hinkwayo, hi nhlayo ya kwalomu ka 1.276 wa timiliyoni ta mavabyi lamantshwa lama vikiweke hi 2018, leswi yimelaka 7,1% wa mavabyi hinkwawo ya khensa eka vavanuna.
Nhlayo ya mafu ya khensa ya nhlaribya ya vununa na yona yi le henhla, hi ku pimanyeta mafu ya 37 005 emisaveni hinkwayo hi 2018.
Hambiswiritano, nhlayo ya lava faka yi hambana hi ku ya hi swifundzha, laha Afrika Vupela-dyambu ri nga ni khombo ra vuntlhanu ro dlayiwa hi khensa ya nhlaribya ya vununa emisaveni hinkwayo, kasi Nigeria ri ni vaaki vo tala ni ikhonomi leyikulu exifundzheni lexi.
Le Nigeria, khensa ya nhlaribya ya vununa hi yona leyi tolovelekeke ngopfu naswona yi dlayaka ngopfu eka vavanuna, hi nhlayo leyi ringanyetiwaka ya 32,8 wa vanhu lava khomiweke hi yona ni lava feke eka 16,3 wa vavanuna va 100 000.
Leswi swi tlula kambirhi nhlayo ya mafu ya le Amerika N'walungu.
Ku va vuvabyi lebyi byi voniwa hi ku famba ka nkarhi, ku kayivela ka mali yo kambela ni ku byi kuma, ku kayivela ka rungula ni ku vikiwa ka mavabyi lawa swi hoxa xandla eka ku andza ka mafu eNigeria.
Le United States, khensa ya nhlaribya ya vununa hi yona ya vumbirhi leyi dlayaka vavanuna vo tala hi khensa, naswona kwalomu ka vavanuna va 40 000 va dlayiwa hi vuvabyi lebyi lembe ni lembe.
Nhlayo ya vanhu lava dlayiwaka hi khensa ya nhlaribya ya vununa yi hunguteke hakatsongo-tsongo ku sukela eku sunguleni ka va-1990, kambe ya ha ri xiphiqo lexikulu xa rihanyo.
Hi ku angarhela, khensa ya nhlaribya ya vununa i vuvabyi lebyi dlayaka, ngopfu-ngopfu etindhawini leti nga riki na vutshunguri ni switirhisiwa swo kambela mavabyi.
Hambiswiritano, ku hatla u swi vona ni ku swi tshungula swi nga antswisa xiyimo xa wena swi tlhela swi hunguta nhlayo ya lava faka.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Xihlambanyo xa vutihlamuleri: swa vutshunguri']
['Website leyi yi endleriwe ku dyondzisa ni ku nyika rungula ntsena naswona a yi nyiki switsundzuxo swa vutshunguri kumbe mintirho ya vativi va swa vutshunguri.']
['Rungula leri nyikeriweke a ri fanelanga ri tirhisiwa ku kambela kumbe ku tshungula xiphiqo xa rihanyo kumbe vuvabyi, naswona lava lavaka xitsundzuxo xa vutshunguri va fanele va vonana ni dokodela la nga ni mpfumelelo.']
['Xiya leswaku ndlela leyi ti-neural net ti hlamulaka swivutiso ha yona a yi pakanisi ngopfu loko ku vulavuriwa hi tinomboro, to tanihi nhlayo ya vanhu lava khomiweke hi vuvabyi byo karhi.']
["Minkarhi hinkwayo kombela xitsundzuxo eka dokodela wa wena kumbe eka muongori la fanelekaka malunghana ni xiyimo xa rihanyo ra wena. U nga tshuki u honisa xitsundzuxo xa dokodela kumbe u hlwela ku xi lava hikwalaho ka leswi u swi hlayeke eka website leyi. Loko u ehleketa leswaku u le xiyin'weni xa xihatla xa rihanyo, bela riqingho eka 911 kumbe u ya ekamareni ra xihatla leri nga ekusuhi na wena hi ku hatlisa. A ku na vuxaka bya dokodela ni muvabyi lebyi tumbuluxiweke hi website leyi kumbe ku tirhisiwa ka yona. BioMedLib kumbe vatirhi va yona, kumbe un'wana ni un'wana la hoxaka xandla eka website leyi, a nga endli switiyisekiso, leswi nga erivaleni kumbe leswi nga erivaleni, malunghana ni rungula leri nga laha kumbe ku tirhisiwa ka rona."]
['Ku ala ku byarha vutihlamuleri: mfanelo yo tsala']
['Nawu wa Digital Millennium Copyright Act wa 1998, 17 U.S.C. § 512 (DMCA) wu nyika tindlela ta ku tihlanganisa na vini va timfanelo ta vuhleri lava va tshembaka leswaku swilo leswi humelelaka eka Internet swi tlula timfanelo ta vona ehansi ka nawu wa vuhleri wa U.S.']
['Loko u tshemba leswaku rungula kumbe swilo leswi kumekaka eka website ya hina kumbe eka mintirho ya hina swi tlula mfanelo ya wena yo endla swilo, wena (kumbe muyimeri wa wena) u nga hi rhumela xitiviso u kombela leswaku rungula kumbe swilo leswi swi susiwa kumbe swi siveriwa.']
['Switiviso swi fanele ku rhumeriwa hi ku tsala hi imeyili (languta eka xiyenge xa "Vuxaka" eka adirese ya imeyili).']
["DMCA yi lava leswaku xitiviso xa wena xa ku tlula nawu wa mfanelo ya ku tsala xi katsa mahungu lawa landzelaka: (1) nhlamuselo ya ntirho lowu nga na mfanelo ya ku tsala lowu ku vuriwaka leswaku wu tluriwile; (2) nhlamuselo ya leswi ku vuriwaka leswaku swi tlula nawu wa ku tsala ni mahungu lama ringaneke ku hi pfumelela ku kuma leswi nga endzeni; (3) mahungu ya ku tihlanganisa na wena, ku katsa ni adirese ya wena, nomboro ya riqingho na adirese ya imeyili; (4) xitiviso xa wena xa leswaku u ni ripfumelo ra leswaku leswi nga endzeni hi ndlela leyi ku vilelaka ha yona a swi pfumeleriwanga hi n'wini wa mfanelo ya ku tsala, kumbe muyimeri wa yena, kumbe hi ku tirha ka nawu wihi na wihi; "]
['(5) xitiyisiso xa wena, lexi sayiniweke ehansi ka nxupulo wa ku hemba, xa leswaku mahungu lama nga eka xitiviso i ntiyiso ni leswaku u na matimba yo tirhisa timfanelo ta vuqambi leti ku vuriwaka leswaku ti tluriwile;']
["na (6) ku sayina ka xiviri kumbe ka elektroniki ka n'wini wa mfanelo ya vuqambi kumbe munhu la pfumeleriweke ku endla hi vito ra n'wini wa mfanelo ya vuqambi. "]
['Loko u nga nghenisi vuxokoxoko hinkwabyo lebyi nga laha henhla swi nga endla leswaku ku tirhana ni xivilelo xa wena swi hlwela.']
['Ku Tihlanganisa']
['Hi kombela u hi rhumela imeyili hi xivutiso/xiringanyeto xihi na xihi.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Hi ku komisa']
['BioMedLib yi tirhisa tikhompyuta leti nga lo endliwa (ti-algorithm ta michini) ku endla swivutiso ni tinhlamulo.']
['Hi sungula hi minkandziyiso ya swa vutshunguri ya 35 wa timiliyoni ya PubMed/Medline. Nakambe, matluka ya Web ya RefinedWeb.']
